Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ralfinamide - Newron Pharmaceuticals

Drug Profile

Ralfinamide - Newron Pharmaceuticals

Alternative Names: NW-1029; Priralfinamide

Latest Information Update: 07 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Newron Pharmaceuticals; Purdue Biopharma
  • Developer Newron Pharmaceuticals
  • Class Amides; Analgesics; Fluorobenzenes; Small molecules
  • Mechanism of Action N type calcium channel antagonists; Nav1.7 voltage-gated sodium channel inhibitors; NMDA receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain; Psychiatric disorders

Highest Development Phases

  • Phase III Neuropathic pain
  • Discontinued Dental pain; Inflammatory pain

Most Recent Events

  • 07 Jan 2020 Ralfinamide is still in phase III for Neuropathic pain in the United Kingdom, Germany, Italy, Poland, Romania and India
  • 09 Sep 2015 Phase-II/III development is still ongoing for Neuropathic pain in the EU and India
  • 21 Aug 2012 Discontinued - Phase-II for Dental pain in India (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top